Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cosmet Dermatol. 2011 Dec;10(4):253-9. doi: 10.1111/j.1473-2165.2011.00581.x.

A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream.

Author information

  • 1Scripps Ranch Dermatology and Cosmetic Center, 9999 Mira Mesa Blvd., San Diego, CA 92131, USA. drtess@scrippsderm.com

Abstract

BACKGROUND:

  Historically, the most effective treatments for skin lightening have contained hydroquinone. However, there is a need for an effective alternative.

AIMS:

  The purpose of this study was to evaluate the skin-lightening efficacy and safety of lignin peroxidase (LIP) creams using a regimen of both day and night products compared with twice-daily application of 2% hydroquinone cream and placebo in Asian women.

PATIENTS/METHODS:

  This was a randomized, double-blind, placebo-controlled, split-face, single-center study of 51 patients. Patients were randomized to receive day and night LIP cream on one randomly selected side of their face and either 2% hydroquinone cream or placebo on the other.

RESULTS:

  A statistically significant change from baseline in the melanin index was observed in LIP-treated skin, with a mean reduction of 7.6% (P < 0.001) on Day 31. Conversely, hydroquinone and placebo did not provide a statistically significant lightening effect when instrumentally measured. Dermatologist scoring demonstrated a significant improvement in overall fairness as early as 8 days after treatment initiation in the LIP-treated group, which was not observed in the other groups. Overall, patients preferred the LIP creams.

CONCLUSIONS:

  The application of day/night LIP cream provided a significantly more rapid and observable skin-lightening effect than hydroquinone 2% cream or placebo.

© 2011 Wiley Periodicals, Inc.

PMID:
22151932
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk